AIMEDBIO

PR

Press Release

AimedBio Licensed-out FGFR3-Targeting ADC AMB302 to Biohaven
2025.01.14

 - AimedBio has entered into an exclusive global licensing agreement with U.S.-based Biohaven for its FGFR3-targeting ADC candidate.

  • - AMB302, granting Biohaven worldwide development and commercialization rights.
  • - Under the agreement, Biohaven will lead the Phase 1 clinical trial in the United States and oversee global clinical development.
  • - Financial terms, including upfront payment and total deal value, were not disclosed.


    Link: https://www.thebionews.net/news/articleView.php?idxno=12088
LIST